Functional constipation (FC) is a common symptom- based gastrointestinal (GI) disorder without organic abnormality, the prevalence of which is between 5% and 20% of the general population.[@b1-jnm-21-4],[@b2-jnm-21-4] The symptoms of constipation can be severe; thus, this disorder has a significant impact on patient\'s quality of life.[@b3-jnm-21-4] The cause of FC remains unclear, especially for slow transit constipation. Alterations of the gut microbiota have been suggested as one possible pathophysiologic mechanism of FC.[@b4-jnm-21-4],[@b5-jnm-21-4] However, the quantitative and/or qualitative changes of the gut microbiota in FC are poorly understood, and many discrepancies exist in the literature.

In the current issue of the *Journal of Neurogastroenterology and Motility*, Kim et al[@b6-jnm-21-4] have published a prospective study in which they investigated the characteristics of gut microbiota in patients with FC using quantitative real-time polymerase chain reaction. The authors found that *Bifidobacterium* and *Bacteroides* species were significantly less abundant in feces from patients with FC compared with healthy controls. However, no significant differences were observed regarding the proportion of *Lactobacillus*, *Escherichia coli* and *Clostridium* species. These results are partially consistent with previous studies that have analyzed the fecal microbiota in patients with FC.[@b7-jnm-21-4],[@b8-jnm-21-4]

*Bifidobacterium* and *Lactobacillus* have been shown to be significantly less abundant in adult patients with constipation.[@b8-jnm-21-4] One study found that patients with constipation predominant-irritable bowel syndrome exhibited significantly less lactate-producing (bifidobacteria and lactobacilli) and lactate-utilizing bacteria in their feces compared with controls; moreover, the abundances of H~2~-consuming populations, methanogens and reductive acetogens were also significantly lower in these patients compared with controls.[@b7-jnm-21-4] In contrast, a study of children with constipation found that the levels of bifidobacteria and clostridia were increased in their feces compared with healthy subjects.[@b9-jnm-21-4] A cross-sectional pilot study using 16S rRNA gene pyrosequencing found that patients with constipation did not exhibit decreased levels of *Lactobacillus* and *Bifidobacterium* species, but did exhibit significantly decreased levels of *Prevotella*.[@b10-jnm-21-4] Regarding methane, the presence of methanogenic bacteria has been shown to be higher in patients with slow transit constipation compared with-non-constipated controls.[@b4-jnm-21-4] These alterations in gut microbiota might be either a cause of FC or a consequence of this condition. Differences in diet or delayed colon transit times might also lead to altered gut microbiota communities in patients with FC. A recent study using humanized (ex-germ-free mice colonized with human fecal microbiota) mice elegantly demonstrated that the composition of the gut microbiota is changed by altered GI motility. Specifically, humanized mice with faster transit due to the administration of polyethylene glycol or a nonfermentable cellulose-based diet exhibited similar changes in gut microbiota composition.[@b11-jnm-21-4] Regardless of whether differences in gut micro-biota are a cause or an effect of constipation, this body of evidence indicates that patients with FC exhibit different compositions of gut microbiota. However, the precise differences in composition are poorly characterized and conflicting data have been found. Thus, no definitive between constipation and the abundance or lack of certain bacterial taxa in the gut microbiome has yet been established.

Kim et al[@b6-jnm-21-4] investigated the efficacy of VSL\#3 probiotics on fecal microbiota and symptom improvement in patients with FC. Mean Bristol stool scores and the numbers of complete spontaneous bowel movements (CSBMs)/week increased significantly in patients with FC treated with VSL\#3. Relief of subjective symptoms including CSBM frequency, stool consistency, and abdominal bloating was reported in up to 70% of patients.

Gut microbiota are clearly associated with GI motility.[@b12-jnm-21-4] In germ free rat model, intestinal bacteria promoted or suppressed the initiation and migration of the migrating myoelectric complex depending on the species.[@b13-jnm-21-4] Gut microbiota can affect intestinal motor functions either directly or indirectly via mediators released by the gut immune response, the end-products of bacterial fermentation, or intestinal neuroendocrine factors.[@b12-jnm-21-4],[@b14-jnm-21-4]--[@b16-jnm-21-4]

Some probiotic bacteria have been shown to stimulate intestinal motility in both animal and human studies. For instance, *Escherichia coli* Nissle 1917 supernatants enhanced colonic contractility by direct stimulation of smooth muscle cells.[@b17-jnm-21-4] Intestinal bacteria have also been shown to stimulate myoelectric activity in the rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex.[@b18-jnm-21-4] Moreover, *Bifidobacterium animalis* DN-173 010 was shown to shorten colonic transit time in healthy women,[@b19-jnm-21-4] and *Bifidobacterium lactis* HN019 supplementation was shown to decrease whole gut transit time in adults with functional GI symptoms.[@b20-jnm-21-4] A meta-analysis of 11 randomized controlled trials (RCTs), consisting of 464 subjects in total, concluded that probiotic supplementation decreased intestinal transit time. Compared with control subjects, patients with probiotic supplementation exhibited a standardized mean difference of 0.40 (95% CI, 0.20--0.59; *P* \< 0.001) in intestinal transit time; this reduction was even more significant in subjects with constipation and older subjects.[@b21-jnm-21-4]

Probiotics may accelerate intestinal transit by decreasing the proliferation of methanogens in patients with FC. Intestinal methanogens can slow intestinal transit via methane production,[@b22-jnm-21-4] since overproduction of methane has been shown to directly inhibit motor activity.[@b23-jnm-21-4] Consistent with these findings, the prevalence of methane-producing bacteria has been shown to be higher in patients with slow transit compared with healthy controls.[@b4-jnm-21-4],[@b24-jnm-21-4] Probiotics may also increase intestinal fermentation and there by enhance colonic peristalsis, which decreases transit time in FC. For instance, colonic fermentation of a physiologically relevant malabsorbed quantity of starch has been shown to significantly increase the number of high amplitude propagated contractions (HAPCs).[@b25-jnm-21-4] Short chain fatty acids (SCFAs), a major end-product of bacterial fermentation, have been shown to increase parietal tone and stimulate ileal propulsive contractions when administered into the human terminal ileum.[@b26-jnm-21-4],[@b27-jnm-21-4] SCFAs have been proposed to stimulate motor responses by releasing neuroendocrine factors and/or lowering the intracolonic pH.[@b27-jnm-21-4],[@b28-jnm-21-4] Animal studies have demonstrated that SCFAs can initiate HAPCs and accelerate intestinal transit and motility via the intestinal release of 5-hydroxytryptamine.[@b29-jnm-21-4] However, a recent human study found no significant differences compared with basal values regarding either the global motility index or the number of HAPCs after intracolonic infusion of acidic solutions or SCFAs. This finding indicates that the increased colonic motor activity induced by bacterial fermentation is not caused by acidification of the colonic contents or the production of SCFAs.[@b30-jnm-21-4] Bacterial fermentation may influence intestinal motility through other mechanisms such as the production of gases, since colonic distension is associated with increased HAPCs,[@b31-jnm-21-4] and/or other fermentation byproducts such as alcohols, ketones and aldehydes.

As aforementioned, intestinal transit can be accelerated by probiotics, however, some other probiotics have been shown to decrease bowel movements, and improve loose stool/diarrhea in patient with diarrhea predominant-irritable bowel syndrome.[@b32-jnm-21-4],[@b33-jnm-21-4] Thus, probiotics may have functions to normalize intestinal motility. Further studies are needed to evaluate the precise effects of gut microbiota and probiotics on GI motility, including the exact effects of fermentation in this process.

A few clinical trials have demonstrated beneficial effects of probiotics in patients with FC. In a recent meta-analysis, 2 RCTs demonstrated that probiotics enhanced the response to therapy in patients with FC.[@b34-jnm-21-4]--[@b36-jnm-21-4] However, this result was not statistically significant (relative risk of failure to respond to therapy = 0.29; 95% CI, 0.07--1.12) and the data were quite heterogeneous. Two trials reported a significant increase in the mean number of bowel movements per week in total of 165 patients (1.49; 95% CI, 1.02--1.96).[@b34-jnm-21-4],[@b36-jnm-21-4],[@b37-jnm-21-4] Another meta-analysis of 14 RCTs (1,182 patients) reported that probiotics significantly reduced whole gut transit time by 12.4 hours, increased stool frequency by 1.3 bowel movements per week, and also improved stool consistency.[@b38-jnm-21-4] However, these results also should be interpreted cautiously due to the high study heterogeneity and risk of bias. The efficacy of probiotics for treating FC has not yet been determined, and more RCTs are needed to evaluate the precise relationship between probiotics and FC.

Finally, Kim et al[@b6-jnm-21-4] performed an elegant study of the compositional changes of the gut microbiota in FC, a process about which little is known, and demonstrated the effect of short-term treatment with VSL\#3 on FC using objective parameters such as CSBM and stool consistency, although this study did not show a generalized view of the diverse fecal microbiota and was not a placebo-controlled trial. These findings are cautiously promising with respect to the use of specific probiotic species in the management of FC. Additional well designed clinical studies are needed to determine the true efficacy of probiotics and to elucidate their mechanisms of action, which may include byproducts of bacterial metabolism such as gas and SCFA, in FC.

Financial support: None.

Conflicts of interest: None.

ORCID: Chang Hwan Choi, <http://orcid.org/0000-0001-7089-532X>.

[^1]: Author contributions: Chang Hwan Choi drafted and edited this article; and Sae Kyung Chang advised on editing draft.
